migraine prophylaxis
Neurology · 2006–2007
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| topiramate Prophylaxis of migraine in adults who have experienced an average of three or more migraines per month over at least six months and who have contraindication… | Mar 2007 | Recommended with restriction | no section in document |
| topiramate Prophylaxis of migraine in adults experiencing an average of three or more migraines per month who have failed or are unable to tolerate beta-blockers and… | Jul 2006 | Not recommended | no section in document |
| topiramate Prophylaxis of migraine in adults experiencing three or more migraines per month who have failed or are unable to tolerate beta-blockers and pizotifen. | Jul 2006 | Not recommended | no section in document |
What the PBS pays
$4M in government benefit over 2024–25, across 228,334 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| topiramate | $4.1M |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| pizotifen malateSANDOMIGRAN pizotifen 0.5mg (as malate) tablet bottle | 1999 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.